Form 4: Bolt Biotherapeutics Director Acquires 22,000 Stock Options

Director Frank D. Lee acquired 22,000 stock options in Bolt Biotherapeutics, Inc. on June 12, 2024.

Summary

• Frank D. Lee, a director of Bolt Biotherapeutics, Inc., acquired 22,000 stock options on June 12, 2024.
• The exercise price of the stock options is $0.7682.
• The options vest on the earlier of June 12, 2025, or the day before the next annual meeting of stockholders, contingent upon continuous service.
• The options will fully vest upon a change in control of the Issuer.
• The expiration date for the options is June 11, 2034.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative sentiment.

Future Outlook

The vesting of the options is contingent upon continuous service and may accelerate upon a change in control of the Issuer.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company directors. It's common for directors to receive stock options as part of their compensation.

Stakeholder Impact

• The acquisition of stock options by a director can align their interests with those of shareholders, potentially incentivizing them to work towards increasing the company's value.

Key Dates